Keynote Presentation at Upcoming International Microbiology & Genomics Meeting to Highlight Ability of Pressure BioSciences' Patented PCT Platform to Improve Testing for Biological Threat Organisms, Human Infectious Diseases, and Contaminated Food Products PCT Processing of Patient and Other Microbial Contaminated Samples Could Potentially Improve Test Quality, Advance Clinical Laboratory Medicine, and Enhance Human Healthcare Worldwide
SOUTH EASTON, Mass., Oct. 31, 2012 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that Dr. Bradford Powell, a prominent microbiologist and recognized infectious diseases expert, is scheduled to present a keynote address during the opening ceremony of this year's annual Clinical Microbiology & Microbial Genomics Conference ("ClinMicro-2012"). ClinMicro-2012 is being held at the Hilton San Antonio Airport from November 12-14, 2012, in San Antonio, TX. In the Keynote address and a second, main session presentation later in the conference, Dr. Powell is expected to present data highlighting the advantages of the Company's powerful and patented Pressure Cycling Technology ("PCT") Platform that have been shown to enable significant improvements in molecular-based microbiological testing, a rapidly growing and extremely important area in laboratory medicine today.
Samples containing infectious microorganisms are often problematic for today's cutting-edge, molecular-based (DNA, RNA, proteins) diagnostic laboratory test methods. Whether testing for biological threat organisms, human infectious diseases, or disease-causing food-borne microbes, highly effective and dependable procedures are required to maintain absolute safety during sample preparation and analysis, yet also preserve sample molecular integrity. Consequently, scientists continue to search for methods that provide both safe decontamination and effective preparation of difficult and potentially dangerous infectious samples.
Dr. Bradford Powell, President of Cernomics Solutions, said: "It has already been demonstrated that the PCT Platform has the ability to inactivate and extract live attenuated virus and bacteria that are used as models of important biological threat agents. To that end, protein and nucleic acid markers from Venezuelan Equine Encephalitis virus and Bacillus anthracis (Sterne) spores were processed in less than an hour, as safely and as effectively as conventional procedures that often require more time, as well as large investments for facilities infrastructure, training, and oversight. Consequently, we are confident that the PCT Platform has the potential to provide an adaptable, cost-effective solution for advancing the capability, safety, and performance of assays used in the clinical and microbial genomics sciences. This is a transformative technology whose time, we believe, has come for broad application and acceptance."
Dr. Nate Lawrence, Vice President of Sales and Marketing of PBI, commented: "We believe that the growing number of PCT applications in basic and applied research, as shown by the work of Dr. Powell and dozens of other researchers over the past several years, promises to expand the understanding of important microorganisms in clinical medicine, anti-bioterror measures, the forensic sciences, and in food safety – as well as in other areas of the life sciences. We believe that this increased understanding of infectious microbes and microbial genomics, aided by the use of our novel PCT Platform, will accelerate the development of improved diagnostics, therapeutics, and food safety measures. We also believe that these clear sample-processing advantages will continue to compel researchers to integrate the PCT Platform into their basic scientific studies and clinical applications, resulting in measurable revenue growth and product visibility for PBI."
About Clinical Microbiology & Microbial Genomics-2012
ClinMicro-2012 is a remarkable event which brings together a unique and international mix of large and medium biotech and diagnostics companies, leading universities, and clinical microbiology institutions making the conference a perfect platform to share experience, foster collaborations across industry and academia, and evaluate emerging technologies across the globe. The meeting is being held at the Hilton San Antonio Airport from November 12-14, 2012 in San Antonio, TX.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.
Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, without limitation, statements regarding the significant improvement in molecular-based microbiological testing for DNA, RNA, and proteins in biological threat organisms, and in samples for human infectious diseases, forensics, and contaminated food; that microbiological testing is a rapidly growing and extremely important area in laboratory medicine today; the conclusions related to the advantages of the PCT Platform reported by Dr. Brad Powell; that samples containing microorganisms are problematic to lab testing; that highly effective and dependable procedures are required to maintain absolute safety during sample preparation and analysis of microbiological samples, and that scientists continue to search for such methods; that the PCT Platform has the potential to provide an adaptable, cost-effective solution in capability, safety, and performance for testing difficult microbial samples, including those for biological threat organisms, human infectious diseases, and contaminated food products; that PCT is a transformative technology whose time for broad application and acceptance has come; that the growing applications of PCT to basic and applied research, as shown by the work of Dr. Powell and dozens of other researchers over the past several years, promises to expand the understanding of important microorganisms in clinical medicine, anti-bioterror measures, the forensic sciences, and in food safety – as well as in other areas of the life sciences; that this increased understanding, brought about to a great extent by the use of the PCT Platform, will aid significantly in the development of improved diagnostics, therapeutics, and food safety measures; and that these clear PCT advantages will continue to compel researchers to include the PCT Platform in their scientific studies, which should result in continued revenue growth and product visibility. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT-based product line; changes in customer's needs and technological innovations; the Company's and its strategic partners/distributors sales forces may not be successful in selling the Company's PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods; that other researchers may not be able to replicate the data reported in the studies mentioned; and if actual operating costs are higher than anticipated, or revenues from product sales are less than anticipated, the Company may need additional capital beyond December 2012. Further, given the uncertainty in the capital markets and the current status of the Company's product development and commercialization activities, there can be no assurance that the Company will secure the additional capital necessary to fund its operations beyond December 2012 on acceptable terms, if at all. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
PBI filed a registration statement (including a prospectus) with the SEC for an offering to which this communication may relate. Before you invest, you should read the prospectus in that registration statement for the offering and other documents PBI has filed with the SEC for more complete information about PBI and the offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, PBI can arrange to send you the prospectus, when available, upon request.
For more information about PBI and this press release, please click on the following link: http://www.pressurebiosciences.com
Richard T. Schumacher, President & CEO
Pressure BioSciences, Inc.
Nate Lawrence, Vice President of Sales & Marketing
(508) 230-1828 (T)
SOURCE Pressure BioSciences, Inc.